Literature DB >> 1565199

Bladder cancer after cyclophosphamide therapy for lupus nephritis.

A Ortiz, E Gonzalez-Parra, G Alvarez-Costa, J Egido.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565199     DOI: 10.1159/000186790

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


× No keyword cloud information.
  6 in total

Review 1.  Clinical trials in lupus nephritis.

Authors:  E M Ginzler
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Curculigo orchioides Gaertn Effectively Ameliorates the Uro- and Nephrotoxicities Induced by Cyclophosphamide Administration in Experimental Animals.

Authors:  Vishnu Priya Murali; Girija Kuttan
Journal:  Integr Cancer Ther       Date:  2015-09-29       Impact factor: 3.279

3.  Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies.

Authors:  Min Zhang; Yizhou Wang; Yutong Wang; Ye Bai; Dongqing Gu
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

Review 4.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

5.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

6.  Incidence of cancer among female patients with systemic lupus erythematosus in Korea.

Authors:  Kwi Young Kang; Hyun Ok Kim; Ho Sung Yoon; Jeniffer Lee; Won Chul Lee; Hyek-Jae Ko; Ji Hyeon Ju; Chul-Soo Cho; Ho-Youn Kim; Sung-Hwan Park
Journal:  Clin Rheumatol       Date:  2009-12-30       Impact factor: 3.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.